Madrigal Pharmaceuticals, Inc.
$551.25 +$6.74 (+1.24%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 20
An insider transaction hit the record.
Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.
RECEIPT: SEC FORM 4, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Mar 26
The stock moved +12.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 26 -
Feb 19
The stock moved -11.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 19
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantati…
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.